


RESEARCH ARTICLE

Open Access



Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity—characterisation and predictive factors from *Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale* (GIRRCS) cohort of patients

Piero Ruscitti^{1*} , Onorina Berardicurti¹, Daniela Iacono², Ilenia Pantano², Vasiliki Liakouli², Francesco Caso³, Giacomo Emmi⁴, Rosa Daniela Grembiale⁵, Francesco Paolo Cantatore⁶, Fabiola Atzeni⁷, Federico Perosa⁸, Raffaele Scarpa³, Giuliana Guggino⁹, Francesco Ciccia², Antonio Barile¹⁰, Paola Cipriani^{1†} and Roberto Giacomelli^{1†}

Abstract

Background: Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown aetiology usually affecting young adults. Interestingly, recent evidence from the juvenile counterpart of AOSD suggested the emergent high fatality rate of lung disease (LD) in these patients. In this work, we aimed to characterise LD in AOSD, to identify associated clinical features and predictive factors, and to describe long-term outcomes of the disease comparing patients with LD and those without.

Methods: A retrospective assessment of prospectively followed patients, from January 2001 to December 2019, was provided to describe the rate of LD in AOSD, associated clinical features and predictive factors, and long-term outcomes. Patients with AOSD, who were included in *Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale* (GIRRCS) cohort, were assessed.

(Continued on next page)

* Correspondence: pioruscitti@live.com; piero.ruscitti@univaq.it

†Paola Cipriani and Roberto Giacomelli contributed equally to this work.

¹Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, delta 6 building, PO box 67100, L'Aquila, Italy
Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Results: Out of 147 patients included in GIRRCs cohort, 18 (12.25%) patients were reported to be affected by LD, at the time of diagnosis of AOSD, who were characterised by older age, a higher prevalence of myalgia, of lymph node involvement, of pleuritis, and abdominal pain. Furthermore, patients with LD showed higher values of systemic score and ferritin. Among those clinical variables, older age and systemic score were also independently predictors of LD. Chest CT scans were also obtained, and the most common finding was the peripheral consolidations in 8 (44.4%) patients. Finally, a higher mortality rate, of 38.9%, was registered in patients with LD than others, since it was associated with a significant decreased survival rate.

Conclusions: The presence of LD could suggest an emergent cause of mortality in AOSD, as observed in juvenile counterpart recognising a further marker of severity and poor prognosis to be carefully evaluated. Patients with LD were also characterised by some clinical features, higher values of systemic score and ferritin than the others, identifying a subset of patients mostly burdened by systemic signs and symptoms. Although specific designed future studies are needed to fully elucidate the significance of LD in AOSD, a more accurate evaluation and management of this feature could improve the long-term outcomes of these patients.

Keywords: Adult onset Still's disease, Lung disease, Mortality

Background

Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown aetiology usually affecting young adults [1]. AOSD is multigenic autoinflammatory disease, defined at the "crossroads" between autoinflammatory and autoimmune diseases due to the pathogenic involvement of both arms of immune system [2]. Spiking fever, arthritis, and evanescent rash are frequently observed during the disease [3]. Other clinical manifestations include sore throat, elevated liver enzymes, lymphadenopathy, liver involvement, splenomegaly, and serositis [3]. Laboratory tests reflect the systemic inflammatory process showing high levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and a typical hyperferritinemia [4]. The latter, despite the poor specificity, is considered strongly suggestive of AOSD, also because of its pathogenic role is supposed [5]. Analysing long-term outcomes of AOSD, one third of patients would usually develop a monocyclic pattern, characterised by a systemic single episode, whereas others either a polycyclic pattern, associated with multiple flares alternating with remissions, or a chronic pattern, related to a persistently active disease [6]. Concerning the therapeutic management, it is mainly aimed at targeting pro-inflammatory signs and symptoms of the disease; therefore, glucocorticoids (GCs), synthetic disease-modifying anti-rheumatic drugs (DMARDs), and, in refractory cases, biologic DMARDs, are used to treat these patients [7–9]. However, despite these therapies, patients with AOSD may experience several flares and life-threatening complications, leading to a mortality rate up to 16% [10]. In fact, AOSD is burdened by severe complications, mostly macrophage activation syndrome (MAS), which are characterised by a high mortality rate in adult patients [11]. Interestingly, recent evidence from the juvenile counterpart of AOSD, the systemic-onset juvenile idiopathic arthritis (SJIA), suggested the emergent high

fatality rate of lung disease (LD) [12, 13]. Despite this finding, few studies, mainly isolated case reports, analysed LD in AOSD so far [14–16], proposing that nearly 5% of patients with AOSD could be affected by LD, with two main patterns, one characterised by an acute respiratory distress syndrome (ARDS), and one with other LDs, including bronchiolitis and nonspecific interstitial lung diseases [16]. On these bases, given the prognostic role of LD in paediatric patients and the inconclusive evidence in adult ones, we aimed to characterise LD in AOSD and to identify associated clinical features and predictive factors. In addition, by analysis of follow-up, we designed a long-term evaluation to describe outcomes of the disease comparing patients with LD and those without.

Materials and methods

Study design, settings, and patients

A retrospective assessment of prospectively followed patients, from January 2001 to December 2019, was provided to describe the rate of LD in AOSD, associated clinical features and predictive factors, and long-term outcomes. Patients with AOSD, who were included in *Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale* (GIRRCs) cohort, were assessed. All patients fulfilled Yamaguchi's criteria for AOSD [17]. The local Ethics Committee (*Comitato Etico Azienda Sanitaria Locale 1 Avezzano/Sulmona/L'Aquila, L'Aquila*, Italy, protocol number 0139815/16) approved the study, which was performed according to the Good Clinical Practice guidelines and the Declaration of Helsinki.

Clinical variables and data sources

By analysis of the clinical charts of patients, clinical features, systemic score, occurrence life-threatening complications, therapies, and patterns of disease were reported, as previously detailed [10, 18]. The clinical workup before

the AOSD diagnosis considered the exclusion of potential mimickers. We assessed infections by blood cultures, bone marrow cultures (in case of MAS), serology, PCR analyses, chest X-rays, and abdominal echography. We also evaluated the possible differential diagnosis with malignancies using chest X-rays, abdominal echography, and blood samples. Despite these exams, in the case of further suspicion, we added CT and/or PET/CT exams to the diagnostic workup. Thus, chest-X-rays were performed in all patients and in those with further suspicion of pulmonary involvement or the need to exclude infections or malignancies chest CT scans were also performed. LD was defined as AOSD-related parenchymal lung involvement as reported in available literature [12, 13, 16]. In patients with suspicion of LD, chest CT scan was performed, and findings codified according to available literature [12, 13]

in different main patterns: (i) multilobar, predominantly peripheral septal thickening, parahilar, and/or anterior upper lobes with or without adjacent ground glass opacities; (ii) crazy-paving; (iii) peripheral consolidations; (iv) peribronchovascular consolidations; (v) predominantly ground-glass opacities [12, 13]. Crazy paving was referred to the appearance of ground-glass opacity with superimposed interlobular septal thickening and intralobular septal thickening, seen on chest CT. Before diagnosing LD related to AOSD, all other possible mimickers were excluded, with more attention to the infectious diseases, as previously performed in SIJA and AOSD [10, 12, 13, 18]. Furthermore, the occurrence of MAS and other AOSD life-threatening complications were assessed, as previously reported [19–21]. Patients in remission were defined as those achieving a complete disappearance of any clinical

Table 1 Descriptive statistics of clinical characteristics of assessed patients with AOSD and grouped according to the presence of LD

Clinical characteristics	18 patients with LD	129 patients without LD	P values, patients with LD vs patients without LD
Age, mean \pm SD	53.6 \pm 14.7 years	44.0 \pm 16.1 years	0.017
Gender, n (%)	9 (50.0) male	80 (62.0) male	0.441
Fever, n (%)	18 (100.0)	129 (100.0)	/
Arthritis, n (%)	16 (88.9)	114 (88.4)	0.654
Skin Rash, n (%)	13 (72.2)	97 (75.2)	0.492
Myalgia, n (%)	16 (88.9)	79 (61.2)	0.033
Splenomegaly, n (%)	14 (77.8)	84 (65.1)	0.215
Lymph node involvement, n (%)	14 (77.8)	66 (51.2)	0.028
Sore throat, n (%)	12 (66.7)	71 (55.0)	0.450
Liver Involvement, n (%)	11 (61.1)	80 (62.0)	0.567
Pleuritis, n (%)	10 (55.5)	19 (14.7)	< 0.001
Pericarditis, n (%)	7 (38.9)	24 (18.6)	0.064
Abdominal Pain, n (%)	8 (44.4)	12 (9.3)	0.001
Systemic score, mean \pm SD	8.4 \pm 2.1	5.7 \pm 1.8	< 0.001
MAS, n (%)	5 (27.8)	21 (16.3)	0.071
Leucocytosis > 15,000/mm ³ , n (%)	11 (61.1)	67 (51.9)	0.318
ESR, mean \pm SD	70.7 \pm 24.7 mm/hr	69.2 \pm 27.7 mm/hr	0.821
CRP, median (interquartile range)	113.1 (99.2) mg/L	77.0 (79.6) mg/L	0.080
Ferritin, median (interquartile range)	3370.5 (3051.8) ng/mL	2841.5 (3545.1) ng/mL	0.010
Low dosage GCs (\leq 0.5 mg/kg/day), n (%)	4 (22.2)	57 (44.2)	0.062
High dosage GCs (> 0.5 mg/kg/day), n (%)	14 (77.8)	72 (55.8)	0.789
Synthetic DMARDs, n (%)	11 (61.1)	84 (65.1)	0.464
Biologic DMARDs, n (%)	5 (27.8)	39 (30.2)	0.536
Monocyclic disease pattern, n (%)	4 (22.2)	47 (36.4)	0.510
Polycyclic disease pattern, n (%)	3 (16.7)	46 (35.6)	0.044
Chronic disease pattern, n (%)	4 (22.2)	34 (26.3)	0.479
Mortality, n (%)	7 (38.9)	13 (10.1)	0.004
Time of follow-up, median (interquartile range)	2.8 (3.4) years	3.9 (3.4) years	0.199

MRI magnetic resonance imaging, *AOSD* adult onset Still's disease, *n* number of patients, *DMARDs* disease-modifying anti-rheumatic drugs, *MAS* macrophage activation syndrome, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *GCs* glucocorticoids. Bolded values are statistically significant ($p < 0.05$)

and laboratory feature of the disease. Inflammatory markers, including ESR, CRP, and ferritin were recorded. At the end of follow-up, patients were categorised into three different disease courses, monocyclic, polycyclic, and chronic patterns, as previously performed [10]. The administration of therapies, glucocorticoids (GCs), synthetic, and biologic DMARDs, for managing AOSD was also registered and categorised, at the time of diagnosis and during the follow-up, as already done [22, 23].

Statistical methods

Statistics firstly provided the descriptive analysis, and collected results were presented as mean and standard deviation (SD) or median and interquartile range (IQR) according to their distribution. Clinical characteristics of patients with and without LD were compared by parametric or non-parametric *t* tests for all the continuous variables, and chi-squared test was used for the categorical ones, as appropriate. Possible correlations among the presence of LD and ESR, CRP, ferritin, and systemic score were estimated by using a point-biserial coefficient correlation. Furthermore, regression analyses were performed to assess possible predictive factors of LD presence. Kaplan-Meier curves were plotted to determine the rates of survival of patients with AOSD with and without LD; the difference between curves was determined by the log-rank (Mantel-Cox) test. Additionally, Cox regression analysis for survival was performed to evaluate the role of LD on mortality of those patients. Due to the relatively simple study design, few retrieved missing data were managed by exclusion of these from analyses. Two-sided *P* values <

0.05 were considered as being statistically significant. The Statistics Package for Social Sciences (SPSS for Windows, version 17.0, SPSS Inc., Chicago, IL, USA) was used for all analyses.

Results

Clinical characteristics of patients with LD

Out of 147 patients included in GIRRCS cohort, 18 (12.25%) patients were reported to be affected by LD, at the time of diagnosis of AOSD. Out of these 18 patients, 8 (44.44%) reported smoking habit, presently or formerly. As detailed in Table 1, these patients were characterised by older age ($p = 0.017$), a higher prevalence of myalgia ($p = 0.033$), of lymph node involvement ($p = 0.028$), of pleuritis ($p < 0.001$), and abdominal pain ($p = 0.001$). Furthermore, patients with LD showed higher values of systemic score ($p < 0.001$) and ferritin ($p = 0.010$). In fact, systemic score (coefficient 0.347, $p < 0.001$) and ferritin (coefficient 0.148, $p = 0.031$) were significantly correlated with LD, whereas ESR (coefficient 0.014, $p = 0.843$) and CRP (coefficient 0.084, $p = 0.220$) did not. In patients with LD, respiratory signs and symptoms were mostly subtle, including mild tachypnoea, dyspnoea, and chronic cough, with a discrepancy between clinical picture and extension of lung involvement. The most common CT finding was the peripheral consolidations in 8 (44.4%) patients, less frequently peribronchovascular consolidations in 4 patients (22.2%), predominantly ground glass opacities in 3 patients (16.7%), crazy-paving in 3 patients (16.7%), and multilobar predominantly peripheral septal thickening in 2 patients (11.1%).




Fig. 1 In this figure, different radiological features of LD, present at the same time, in a patient with AOSD are shown as follows: **a** crazy paving (white arrow), **b** crazy paving (white arrow), **c** peribronchovascular consolidations with ground glass, and **d** peripheral consolidation

Most showed one or more of these patterns, which appeared to be not mutually exclusive. In almost all patients, 14 out of 18 (77.8%), a follow-up evaluation of chest CT scan was retrieved, but analysed without any inferential analysis due to the lack of power. In patients, who improved, a complete disappearance of inflammatory findings was reported, whereas in others a worsening of LD was observed. In Fig. 1, representative images of chest CT findings of LD related AOSD are shown, whereas in Fig. 2, disappearance or worsening of inflammatory signs are reported after therapy. In these patients, no evidence of clinical pulmonary hypertension, of ARDS, and clubbing was reported. Finally, unusual adverse drug reactions were not retrieved.

Predictive factors of LD

Considering the prognostic role of LD presence, at the time of diagnosis, possible predictive factors of this feature were tested. By univariate analyses, age (OR = 1.04, 95%CI = 1.01–1.07, $p = 0.021$), myalgia (OR =

5.06, 95%CI = 1.12–22.97, $p = 0.036$), lymph node involvement (OR = 3.34, 95%CI = 1.04–10.69, $p = 0.042$), pleuritis (OR = 7.34, 95%CI = 2.53–20.67, $p < 0.001$), abdominal pain (OR = 7.80, 95%CI = 2.59–23.51, $p < 0.001$), and systemic score (OR = 2.14, 95%CI = 1.54–2.97, $p < 0.001$) were retrieved to be significantly predictive on the likelihood of LD presence. Based on the results of univariate analyses, a multivariate regression model was built to evaluate the independent predictive role of selected variables (age and systemic score) on the likelihood of LD presence, at the time of diagnosis (Table 2). Despite the significant results of univariate analyses, we selected the systemic score to be added in the multivariate analysis since including all other clinical variables and due to the low number of patients with LD. The multivariate analysis showed that older age (OR = 1.04, 95%CI 1.01–1.08, $p = 0.044$) and systemic score (OR = 2.08, 95%CI = 1.50–2.88, $p < 0.001$) were independently predictors on the likelihood of LD presence. Considering the reported prognostic role of systemic score ≥ 7 on




Fig. 2 In this figure, radiological features of LD, in patients with AOSD, before and after therapies are shown. In panel **a**, a peribronchovascular consolidation is shown (white arrow) which is completely disappeared after therapy with high dosage of GCs, as shown in panel **b**. In panel **d**, the occurrence of ground glass opacities is reported, after previous negative findings, as shown in panel **c**. In panel **f**, the occurrence of peripheral consolidations (white arrows) with concomitant pleural effusion (black arrow) is reported, after previous negative findings, as shown in panel **e**

Table 2 Regression analyses of predictive factors on the likelihood of LD presence in AOSD

Clinical variables	OR	95%CI	<i>p</i>
<i>Univariate analyses</i>			
Age	1.04	1.01–1.07	0.021
Male gender	0.61	0.23–1.65	0.332
Arthritis	1.05	0.22–5.04	0.95
Skin Rash	0.86	0.28–2.59	0.786
Myalgia	5.06	1.12–22.97	0.036
Splenomegaly	1.87	0.58–6.03	0.290
Lymph node involvement	3.34	1.04–10.69	0.042
Sore throat	1.63	0.58–4.62	0.355
Liver Involvement	0.96	0.35–2.65	0.941
Pleuritis	7.34	2.53–20.67	< 0.001
Pericarditis	2.78	0.98–7.92	0.060
Abdominal pain	7.80	2.59–23.51	< 0.001
Systemic score	2.14	1.54–2.97	< 0.001
Systemic score ≥ 7	19.16	4.20–87.41	< 0.001
MAS	1.39	0.42–4.62	0.592
Leucocytosis $> 15,000/\text{mm}^3$	1.45	0.53–3.99	0.467
ESR	1.01	0.98–1.02	0.819
CRP	1.32	0.85–2.06	0.214
Ferritin	1.48	0.95–2.31	0.083
Low dosage of GCs	0.36	0.11–1.16	0.086
Synthetic DMARDs	0.84	0.30–2.32	0.739
Biologic DMARDs	0.88	0.29–2.66	0.831
Monocyclic Pattern	0.87	0.31–2.48	0.798
Polycyclic disease pattern	0.23	0.05–1.02	0.064
Chronic disease pattern	0.80	0.25–2.59	0.708
<i>Multivariate analyses</i>			
Age	1.04	1.01–1.08	0.044
Systemic score	2.08	1.50–2.88	< 0.001
$\chi^2 = 28.72, p < 0.001$			
Age	1.05	1.01–1.09	0.011
Systemic score ≥ 7	23.31	4.85–42.08	< 0.001
$\chi^2 = 23.06, p < 0.001$			

MRI magnetic resonance imaging, AOSD adult onset Still's disease, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GCs glucocorticoids, DMARDs disease-modifying anti-rheumatic drugs. Bolded values are statistically significant ($p < 0.05$)

mortality in AOSD [10], we tested systemic score also as dichotomy (“yes systemic score ≥ 7 ”/“no systemic score ≥ 7 ”). Systemic score ≥ 7 resulted to be a significant predictor on the likelihood of LD presence, in univariate analysis (OR = 19.16, 95%CI = 4.20–87.41, $p < 0.001$) as well as in multivariate analysis (OR = 23.31, 95%CI = 4.85–42.08, $p < 0.001$).

Survival rate of patients with LD

A higher mortality rate ($p = 0.004$), of 38.9%, was registered in patients with and LD than the others. In these patients, no specific chest CT scan pattern was retrieved. Specifically, 5 patients died from uncontrollable MAS, 1 from multiple organ failure with the liver and kidney failures, and 1 from severe infection related to the immunosuppressive therapy, whereas no death due to ARDS was registered in our cohort. The presence of LD, at the time of diagnosis, was significantly associated with a decreased survival rate of patients ($p < 0.001$) during the follow-up, as shown in Fig. 3. Furthermore, the presence of LD, at the time of diagnosis, significantly predicted the mortality in both univariate (HR = 4.81, 95%CI = 1.91–12.12, $p = 0.001$) and in age- and gender-adjusted multivariate (HR = 3.41, 95%CI = 1.28–9.12, $p = 0.014$) analyses for survival.

Discussion

In the present evaluation, the assessment of LD was performed in a large cohort of patients with AOSD, analysing associated clinical characteristics, predictive factors, and long-term outcomes. Patients with LD were characterised by some clinical features, higher values of systemic score and ferritin, than those without. Some clinical variables, older age and systemic score, were retrieved to be clinical independent predictors on the likelihood of LD presence. Analysing the follow-up, a higher mortality rate was observed in patients with LD, thus identifying an additional marker of severity and poor prognosis to be carefully evaluated in AOSD.

In this cohort, 12.25% of patients with AOSD were reported to be affected by LD. This result could suggest a higher rate than reported in available literature [16], but it must be pointed out that mainly isolated case reports investigated this issue [14–16], thus limiting the validity of this estimation in adults. Clinically, as observed in SJIA, patients with AOSD-related LD showed a striking dissociation between relatively subtle clinical features, including mild tachypnoea, dyspnoea, chronic cough, and the extension of the inflammatory process in lungs based on chest CT. Furthermore, patients with LD were characterised by a higher prevalence of myalgia, of lymph node involvement, of pleuritis, and abdominal pain, than others. In addition, those patients showed higher values of systemic score and ferritin. Except from the higher levels of ferritin, different clinical characteristics were retrieved comparing patients with LD with either SJIA or AOSD [12, 13]. In fact, we did not observe any evidence of clinical pulmonary hypertension, of ARDS, clubbing, and unusual adverse drug reactions. In spite of a continuum of the disease is proposed between paediatric and adult patients [24], some dissimilarities, from both clinical and pathogenic




Fig. 3 Kaplan-Meier curves of survival in patients with or without LD. The presence of LD was significantly associated with a decreased survival rate of patients with AOSD ($p < 0.001$)

point of views, are reported [25–27], suggesting the need of further studies, specifically designed and adequately powered, to fully investigate this issue. In the present evaluation, findings of chest CT scan were analysed and the most common pattern was the peripheral consolidations in 44.4% of patients, differently from what observed in paediatric patients [12, 13].

Furthermore, despite the lack of power, the results about chest CT scans, which were obtained after the therapies, suggested that LD could also follow the activity of the disease, reducing or enhancing according to the achievement of remission or not. Analysing predictive factors of LD, at the time of diagnosis, older age, and higher systemic score resulted to be independent predictors of LD in AOSD. The predictive role of older age seems to be conflicting with findings on paediatric ages, possibly suggesting the role of environmental or occupational factors, such as smoking history or specific dietary habit, to be studied in worsening the course of the disease. Systemic score is a prognostic clinical tool which may be applied to patients with AOSD, identifying, at the time of diagnosis, those patients with the likelihood of a more severe outcome [10]. In addition, a cut-off at 7.0 of the systemic score would identify those patients at higher risk of AOSD-related death, confirming that the multi-organ involvement at the time of diagnosis is a

predictive factor of a more severe outcome and increased mortality [10, 25]. Taking together all these features about LD in AOSD, a subset of patients could be identified, mostly characterised by a systemic signs and symptoms of the disease.

Analysing the follow-up of these patients, the presence of LD reduced the survival rate of patients with AOSD, since associated with about 40% of mortality, mirroring what observed in SJIA [12, 13, 28, 29], and suggesting a careful evaluation of this feature. In these patients, no specific chest CT scan pattern was retrieved, suggesting that further studies are needed to fully elucidate this issue. The higher mortality rate observed in our study did not confirm results from other European AOSD series [30, 31], but paralleled with data reported on Asiatic populations [32, 33]. In patients with LD, the main cause of death was the occurrence of uncontrollable MAS and not the occurrence of ARDS. This result mirrored the association between LD and MAS reported in SJIA [12, 13]. In those patients, it has been suggested that the lung involvement may trigger the systemic inflammation and the development of this hyperinflammatory complication [34, 35]. In this context, the IFN- γ may play a central pathogenic role. In fact, in biopsies of lung in patients with SJIA, the analysis of expressed genes revealed that many of the upregulated targets were

in gene pathways related to the IFN- γ response, including HLA-D family members and other IFN-related genes [13]. Furthermore, two of the most highly upregulated non-HLA genes were CXCL9 and CXCL10 [13], IFN-induced chemokines strongly correlated with the occurrence of MAS [36, 37]. In addition, the lung is one of the major physiological producers of IL-1 and IL-6, which are also involved in pathogenic steps leading to occurrence of MAS [34, 35, 38, 39]. Thus, it is possible to suggest that the lung involvement observed in these patients, either SIJA or AOSD, could act as a trigger to excessively amplify the immune response, leading to a massive release of pro-inflammatory mediators and, finally, to the occurrence of MAS.

Despite providing an analysis of LD in AOSD, the present evaluation is affected by different limitations associated with the retrospective design, which is affected by different biases. In addition, due to the retrospective design, we did not have contrast enhancement CT scan and lung biopsies, as in paediatric patients [12, 13]. Furthermore, considering the retrospective design and the discrepancy between subtle symptoms and the extension of LD, it is also possible that the first line assessment with chest X-rays could have miss a percentage of patients by minimal pulmonary symptoms. However, although our results should be carefully generalised, it must be pointed out that the rarity of AOSD would make difficult to arrange prospective studies. This is a common unmet need when dealing with rare diseases [40, 41], thus suggesting the significance of retrospective studies to identify relevant clinical features in generating hypotheses to be subsequently investigated and confirmed.

Conclusions

In conclusion, the presence of LD could suggest an emergent cause of mortality in AOSD, as observed in SJIA, recognising a further marker of severity and poor prognosis to be carefully evaluated. Patients with LD were also characterised by some clinical features, higher values of systemic score and ferritin than the others, identifying a subset of patients mostly burdened by systemic signs and symptoms. Although specific designed future studies are needed to fully elucidate the significance of LD in AOSD, a more accurate evaluation and management of this feature could improve the long-term outcomes of these patients.

Abbreviations

AOSD: Adult-onset Still's disease; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; GCs: Glucocorticoids; DMARDs: Disease-modifying anti-rheumatic drugs; MAS: Macrophage activation syndrome; SJIA: Systemic-onset juvenile idiopathic arthritis; LD: Lung disease; ARDS: Acute respiratory distress syndrome; GIRRCs: Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale; SD: Standard deviation; IQR: Interquartile range

Acknowledgements

The authors thank Mrs. Federica Sensini for her technical assistance.

Authors' contributions

All authors made substantial contributions to the conception or design of the work, the acquisition, and interpretation of data. All authors contributed to the critical review and revision of the manuscript and approved the final version. All the authors agreed to be accountable for all aspects of the work.

Funding

No funding for this study.

Availability of data and materials

All data relevant to the study are included in the article.

Ethics approval and consent to participate

The local Ethics Committee (*Comitato Etico Azienda Sanitaria Locale 1 Avezzano/Sulmona/L'Aquila, L'Aquila*, Italy, protocol number 0139815/16) approved the study, which was performed according to Good Clinical Practice guidelines and the Declaration of Helsinki. After approval of our ethics committee, we collected written informed consents for patients presently and actively followed-up in each centre for the use of de-identified clinical and laboratory data and images for study purposes. However, since the retrospective nature of the study, for those patients who were not anymore followed-up (lost to follow-up or died during the time-period of assessment), after having made every reasonable effort to contact them, we used the fully anonymized clinical data according to the Italian Law on privacy only for research purposes without any other intended aim (*Garante per la protezione dei dati personali, Autorizzazione n. 9/2016 - Autorizzazione generale al trattamento dei dati personali effettuato per scopi di ricerca scientifica - 15 dicembre 2016* [5805552]).

Consent for publication

Not applicable, all the patients' data are de-identified.

Competing interests

The authors declare that they have no conflicts of interest for this work.

Author details

¹Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, delta 6 building, PO box 67100, L'Aquila, Italy. ²Rheumatology Section, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. ³Rheumatology Unit, Department of Clinical Medicine and Surgery, School of Medicine, University of Naples Federico II, Naples, Italy. ⁴Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy. ⁵Department of Health Sciences, University of Catanzaro "Magna Graecia", Catanzaro, Italy. ⁶Rheumatology Unit, Department of Medical and Surgery Sciences, University of Foggia, Foggia, Italy. ⁷Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. ⁸Rheumatic and Systemic Autoimmune Diseases Unit, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Bari, Italy. ⁹Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology section, University of Palermo, Palermo, Italy. ¹⁰Diagnostic and Interventional Radiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Received: 11 March 2020 Accepted: 12 June 2020

Published online: 22 June 2020

References

- Ruscitti P, Giacomelli R. Pathogenesis of adult onset still's disease: current understanding and new insights. *Expert Rev Clin Immunol*. 2018;14:65–976.
- Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. *Autoimmun Rev*. 2014;13:708–22.
- Fautrel B. Adult onset Still's disease. *Best Pract Res Clin Rheumatol*. 2008;22:773–92.
- Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. *Nat Rev Rheumatol*. 2018;14:603–18.
- Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's

- disease, septic shock and catastrophic antiphospholipid syndrome. *BMC Med.* 2013;11:185.
6. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. *J Autoimmun.* 2018;93:24–36.
 7. Li S, Zheng S, Tang S, Pan Y, Zhang S, Fang H, Qiao J. Autoinflammatory pathogenesis and targeted therapy for adult-onset Still's disease. *Clin Rev Allergy Immunol.* 2020;58:71–81.
 8. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. *Expert Rev Clin Immunol.* 2014;10:1519–30.
 9. Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies. *Expert Rev Clin Immunol.* 2017;13:1089–97.
 10. Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccio F, Liakouli V, et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. *BMC Med.* 2016;14:194.
 11. Ruscitti P, Cipriani P, Ciccio F, Masedu F, Liakouli V, Carubbi F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. *Autoimmun Rev.* 2017;16:16–21.
 12. Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. *Ann Rheum Dis.* 2019;0:1–10.
 13. Schuler G, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. *Arthritis Rheumatol.* 2019;71:1943–54.
 14. Sato H, Yokoe I, Nishio S, Onishi T, Takao T, Kobayashi Y, et al. A case of adult onset Still's disease complicated with cryptogenic organizing pneumonia. *Intern Med.* 2011;50:247–51.
 15. Ak O, Ozer S, Cağ Y, Karagöz G. An adult onset Still's disease mimicking pneumonia. *Rheumatol Int.* 2012;32:2539–41.
 16. Gerfaud-Valentin M, Cottin V, Jamilloux Y, Hot A, Gaillard-Coadon A, Durieu I, et al. Parenchymal lung involvement in adult-onset still disease: a STROBE-compliant case series and literature review. *Medicine.* 2016;95(30):e4258.
 17. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol.* 1992;19:424–30.
 18. Ruscitti P, Iacono D, Ciccio F, Emmi G, Cipriani P, Grembale R, et al. Macrophage activation syndrome in patients affected by adult onset Still's disease: analysis of survival rate and predictive factors in GIRCCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. *J Rheumatol.* 2018;45:864–72.
 19. Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still's disease. *Clin Rheumatol.* 2014;33:305–14.
 20. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. *Arthritis Rheumatol.* 2014;66:2613–20.
 21. Batu ED, Erden A, Seyhoğlu E, Kilic L, Büyüksak Y, Karadag O, et al. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. *Scand J Rheumatol.* 2017;46:44–8.
 22. Ruscitti P, Cipriani P, Liakouli V, Guggino G, Carubbi F, Berardicurti O, et al. Managing adult-onset Still's disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. *Medicine (Baltimore).* 2019;98:e15123.
 23. Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Caso F, et al. Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. *Rheumatol Int.* 2020;40:107–13.
 24. Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. *Pediatr Rheumatol Online.* 2015;13:50.
 25. Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, et al. Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. *Clin Rheumatol.* 2017;36:2839–45.
 26. Pay S, Türkçapar N, Kalyoncu M, Simşek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. *Clin Rheumatol.* 2006;25:639–44.
 27. Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A. Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis. *Clin Immunol.* 2016;169:8–13.
 28. Athreya BH, Doughty RA, Bookspan M, Schumacher HR, Sewell EM, Chatten J. Pulmonary manifestations of juvenile rheumatoid arthritis: a report of eight cases and review. *Clin Chest Med.* 1980;1:361–74.
 29. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken).* 2013;65:745–52.
 30. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. *Medicine (Baltimore).* 2014;93:91–9.
 31. Kalyoncu U, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: data from a large multicenter cohort. *J Autoimmun.* 2016;69:59–63.
 32. Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still's disease. *Rheumatol Int.* 2012;32:1291–8.
 33. Zeng T, Zou YQ, Wu MF, Yang CD. Clinical features and prognosis of adult-onset Still's disease: 61 cases from China. *J Rheumatol.* 2009;36:1026–31.
 34. Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Carubbi F, Berardicurti O, et al. Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? *Expert Rev Clin Immunol.* 2017;13:1041–7.
 35. Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O, Carubbi F, et al. H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. *Clin Exp Immunol.* 2018;191:220–8.
 36. Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon- γ and interferon- γ -induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *Ann Rheum Dis.* 2017;76:166–72.
 37. Liu Y, Lightfoot YL, Seto N, Carmona-Rivera C, Moore E, Goel R, et al. Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR7-dependent lupus. *JCI Insight.* 2018;3:124729.
 38. GTEx Consortium. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science.* 2015;348:648–60.
 39. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. *Nat Rev Rheumatol.* 2016;12:259–68.
 40. Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? the unmet needs and the clinical grey zone in autoimmune disease management. *Autoimmun Rev.* 2017;16:911–24.
 41. Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Onorina Berardicurti O, Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. *Autoimmun Rev.* 2019;18:93–106.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

